Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

Barclays PLC raised its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1,269.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,641 shares of the company’s stock after purchasing an additional 5,229 shares during the period. Barclays PLC’s holdings in MoonLake Immunotherapeutics were worth $283,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd increased its stake in shares of MoonLake Immunotherapeutics by 55.4% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 20,325 shares of the company’s stock valued at $1,025,000 after purchasing an additional 7,247 shares during the last quarter. State Street Corp grew its position in MoonLake Immunotherapeutics by 96.2% in the third quarter. State Street Corp now owns 87,637 shares of the company’s stock valued at $4,419,000 after acquiring an additional 42,980 shares during the last quarter. Parkman Healthcare Partners LLC grew its position in MoonLake Immunotherapeutics by 1.6% in the third quarter. Parkman Healthcare Partners LLC now owns 102,813 shares of the company’s stock valued at $5,184,000 after acquiring an additional 1,589 shares during the last quarter. HighVista Strategies LLC raised its stake in MoonLake Immunotherapeutics by 3.1% during the third quarter. HighVista Strategies LLC now owns 43,541 shares of the company’s stock worth $2,195,000 after acquiring an additional 1,292 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of MoonLake Immunotherapeutics in the third quarter worth about $741,000. 93.85% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on MLTX. Wedbush reaffirmed an “outperform” rating and set a $73.00 price target (down from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, November 5th. The Goldman Sachs Group raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $62.00 to $82.00 in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Monday, September 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $84.29.

MoonLake Immunotherapeutics Stock Performance

Shares of NASDAQ MLTX opened at $43.81 on Tuesday. The firm has a 50 day moving average price of $51.43 and a two-hundred day moving average price of $49.06. The stock has a market cap of $2.80 billion, a P/E ratio of -33.96 and a beta of 1.31. MoonLake Immunotherapeutics has a 52-week low of $37.55 and a 52-week high of $64.98.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the prior year, the company earned ($0.18) EPS. Analysts predict that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.